Motesanib

Advanced Solid Tumors

AmgenSmall moleculePhase 1Dormant

C

36/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 29/ 100
Competitive Position: 59/ 100

Competitive context

1412 Active assets in the Advanced Solid Tumors cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

Motesanib is also rated in:

non-small cell lung carcinomaDormant

CCC

Indicative ·

53 / 100

pancreatic neuroendocrine tumorDormant

CC

Indicative ·

47 / 100

digestive system neuroendocrine tumor, grade 1/2Dormant

CC

Indicative ·

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.